Potassium Carbonate → 1-[2-(2,1,3-Benzoxadiazol-5-yl)ethyl]-4-[2-(4-nitrophenyl)ethyl]piperazin-2-one
Reaction equation
[N:1]1[O:2][N:3]=[C:4]2[CH:9]=[C:8]([CH2:10][CH2:11][N:12]3[CH2:17][CH2:16][NH:15][CH2:14][C:13]3=[O:18])[CH:7]=[CH:6][C:5]=12.I[CH2:20][CH2:21][C:22]1[CH:27]=[CH:26][C:25]([N+:28]([O-:30])=[O:29])=[CH:24][CH:23]=1.C([O-])([O-])=O.[K+].[K+]>CN(C=O)C>[N:1]1[O:2][N:3]=[C:4]2[CH:9]=[C:8]([CH2:10][CH2:11][N:12]3[CH2:17][CH2:16][N:15]([CH2:20][CH2:21][C:22]4[CH:23]=[CH:24][C:25]([N+:28]([O-:30])=[O:29])=[CH:26][CH:27]=4)[CH2:14][C:13]3=[O:18])[CH:7]=[CH:6][C:5]=12Participants
5
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of 1-[2-(2,1,3-Benzoxadiazol-5-yl)ethyl]piperazin-2-one (20 mg, 0.081 mmol) in DMF (1 mL) was added 1-(2-Iodoethyl)-4-nitrobenzene (27 mg, 0.097 mmol) and K2CO3 (45 mg, 0.32 mmol). The mixture was allowed to stir at RT for 16 hours. LC showed product formation. The desired product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA). LC-MS (IE, m/z): 396 [M+1]+.
Workup
- customThe desired product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA)
Sources & evidence
- ORD record
- ord-30debf0cfe1a4600a3ddf32af340f3eb
- Source dataset
- uspto-grants-2015_04
- Patent number
- US08999990B2
Reaction notes
Loading…